Expert Perspective: FDA CRDAC Vote on Patisiran for ATTR-CM,

Ahmad Masri, MD, MS, provides his perspective on the APOLLO-B data and reacts to the FDA CRDAC 9 to 3 vote in favor of the benefit-risk profile for patisiran in ATTR-CM.

Related Keywords

Oregon , United States , Javed Butler , Ahmad Masri , Baylor Scott , Science University Ahmad Masri , Science University , Renal Drugs Advisory Committee , Drug Administration Cardiovascular , Advisory Committee , Division Of Cardiovascular Medicine , Oregon Health , Hypertrophic Cardiomyopathy Center At Oregon Health , White Research Institute , Drug User Fee Act Target Action , Drug Administration , Kansas City Cardiomyopathy Questionnaire , White Research , Cardiovascular Medicine , Hypertrophic Cardiomyopathy Center , Fda Crdac , Patisiran , Attr Cm , Cardiomyopathy , Alnylam ,